The effect of hypertension comorbidity in type 2 diabetes on inflammation, cardiovascular risk and hepatorenal function.

Abstract

The prevalence of non‐communicable diseases such as type 2 diabetes mellitus (T2D) has rapidly increased over the years and has exerted a major burden on health systems worldwide. T2D is one of the top ten leading causes of global mortality driven by various T2D‐related complications such as cardiovascular disease (CVD) and altered hepatorenal function. Notably, hypertension (HTN) is the most common comorbidity in T2D, with both being independent risk factors for CVD. Although the underlying pathophysiological mechanisms for this bi‐directional relationship are multifactorial, chronic inflammation is implicated in the progression of T2D and the pathogenesis of its associated complications. Since HTN is at least in part, an immune‐mediated inflammatory disorder, this study aimed at investigating its compounding effects in T2D on inflammation, cardiovascular risk and hepatorenal function.